Drug makers Pfizer and BioNTech's Covid-19 vaccine could secure emergency US and European authorisation next month after final trial results showed a 95% success rate with no serious side effects.
The US Food and Drug Administration (FDA) could grant emergency-use by the middle of December, and conditional . . .
Please Login to read all contents for free.